Monthly information on share capital and company voting rights
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025. The release lists the total number of shares and total voting rights recorded on that date.
- ISIN: FR0010425595
- Date: 12/31/2025
- Total shares: 100,339,441
- Total voting rights: 105,576,356
Contact details for media and investor relations were provided for further information.
Details
News Market Reaction – CLLS
On Jan 6, the first trading day after this news, CLLS closed 3.08% below the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Total shares
- 100,339,441
- Share capital as of 12/31/2025
- Total voting rights
- 105,576,356
- Voting rights as of 12/31/2025
Historical Context
-
Arbitral Tribunal decision partially terminating a license and dismissing other claims.
-
ASH 2025 Phase 1 NATHALI-01 eti-cel data with high ORR and CR rates.
-
Monthly disclosure of total shares and voting rights as of November 30, 2025.
-
Nature Communications paper on non-viral CssDNA gene insertion with high efficiency.
-
Q3 2025 results with multiple CAR-T efficacy data points and stronger revenue.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
isin financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, Jan. 05, 2026 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 12/31/2025 | 100,339,441 | 105,576,356 |
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.